Monsanto Company Earnings: Would a Syngenta Buyout Boost Growth?

On Wednesday, Monsanto (NYSE: MON  ) will release its quarterly report, and shareholders have sent the stock soaring to its best levels since the agricultural boom right before the financial crisis hit. Yet even as Monsanto has done a good job of outpacing DuPont (NYSE: DD  ) and other rivals with its early move to focus on high-margin ag products, recent reports that the company considered buying Syngenta (NYSE: SYT  ) has some investors wondering if Monsanto thinks it needs to turn to the M&A front to bolster its future growth.

Monsanto is a company that draws strong opinions from both proponents and opponents of the company. Investors have unquestionably benefited from the huge growth that the fertilizer and seed-maker has seen during the farming boom, as strong crop prices have encouraged farmers to use crop-yield-enhancing techniques to take full advantage of high demand. Yet critics argue that Monsanto's emphasis on genetically modified organisms threatens the food supply and the trading position of U.S. growers in relation to reluctant partners overseas. Let's take an early look at what's been happening with Monsanto over the past quarter and what we're likely to see in its report.

Source: Monsanto.

Stats on Monsanto

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$4.41 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Have Monsanto earnings seen their best days?
Investors have slashed their views on Monsanto earnings in recent months, cutting May-quarter estimates by 13%. Yet they don't see major problems further into the future, and the stock has responded favorably, rising more than 7% since mid-March.

Monsanto's fiscal second-quarter report in early April showed just how important the company's focus on seeds and genomic products has been to its overall growth. Even though a cold winter led to delays in shipments of products, Monsanto's net sales rose almost 7% from year-earlier figures. In particular, seeds sales in the soybean arena have risen substantially, offsetting weakness in corn planting. Margins improved, and Monsanto's products have demonstrated advantages over previous products, which could lead to further growth. Overall, the strong results from seeds has been a big part of why DuPont, Syngenta, and other players in the chemicals industry have moved so aggressively toward the agricultural side of the business.

Source: Ben Collins/Flickr.

Another way that Monsanto has profited from its expertise is through licensing payments from rivals. DuPont and Monsanto agreed to a licensing agreement that has greatly enhanced Monsanto's cash flow. As long as Monsanto's research and development keeps it ahead of its peers, then similar deals could add a substantial amount of incremental revenue to its direct sales of products to agricultural professionals.

Still, Monsanto faces huge opposition overseas. In particular, the Russian government has been quite vocal lately in its disdain for Monsanto, with Russian officials comparing the company to a terrorist organization and seeking to pass laws imposing criminal fines on the producers of biotech-aided crops. Of course, DuPont, Syngenta, and others also make genetically modified seeds and therefore would face the same issues, but Monsanto has come to be the face of the anti-GMO movement.

In that context, speculation about a possible Monsanto buyout of Syngenta has been interesting. Syngenta is a Swiss company, which would potentially allow Monsanto to move its tax domicile outside the U.S. and therefore escape high corporate taxation. Yet there might be other potential benefits to consolidation in the industry, including economies of scale and synergies related to production and transportation. Yet the deal would be huge, with Syngenta having a market cap of more than half of Monsanto's, and financing a buyout might be difficult even with low interest rates prevailing.

In the Monsanto earnings report, watch to see if the company comments on the Syngenta buyout reports. Given the premiums that companies have had to pay to make overseas acquisitions lately, shareholders might want to root against a Syngenta-Monsanto merger, at least in the short run.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Click here to add Monsanto to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 24, 2014, at 8:06 AM, funfundvierzig wrote:

    Monsanto is the fortress of a front-runner, maintaining and increasing the gap with its nearest lagging competitor, DuPont, in seed biotechnology and production. DuPont's inferior position is confirmed by the fact it shells out hundreds of $millions in license fees to Monsanto every year in order to put Monsanto's superior GM traits into Pioneer's otherwise rather conventional seed line-up.

    Ellen Kullman, DuPont Chieftess is futilely trying to give the struggling DuPont conglomerate a Monsanto Makeover, shedding chemicals and materials. But she is a decade too late, with too little scientific talent, as demonstrated so dramatically with the colossal failure of dandelion herbicide, DuPont Imprelis. Imprelis killed and damaged hundreds of thousands of mature landscaping trees across the country, including hundreds of trees at the old DuPont Country Club! Cost to DuPont shareholders: Well over $1 billion in litigation, settlements and other costs.


Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3005346, ~/Articles/ArticleHandler.aspx, 9/2/2015 6:47:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:02 PM
DD $50.02 Down -1.48 -2.87%
E.I. du Pont de Ne… CAPS Rating: ****
MON $95.80 Down -1.85 -1.89%
Monsanto CAPS Rating: ***
SYT $68.63 Down -0.71 -1.02%
Syngenta CAPS Rating: *****